i3 Frequently Asked Questions
Launched by MSIP, the i3 series offers a variety of technology commercialization funding for Mount Sinai innovators. There are three different opportunities that make up the series, with different criteria in an effort to enable a wide range of inventors from Mount Sinai’s research and clinical communities.
“i3” stands for innovation, inflection, and impact, the three ingredients necessary to expediate commercializing relevant inventions and transforming a research idea into a mature, commercial-ready technology.
- i3 Accelerator (launched in 2018): milestone-based funding for more established healthcare technologies with potential for commercial translation
- i3 Genesis (launched in January 2022): funding for early-stage healthcare discoveries with the potential to become commercialized
- i3 Prism (launching March 2022): funding for technology commercialization efforts by female and/or minority innovators
Each opportunity of the i3 series can support technologies from all healthcare fields (for example: therapeutics, diagnostics, medical devices, digital health, and more). Each opportunity has its own eligibility and requirements. To learn more, please visit the i3 Genesis, i3 Accelerator, and/or i3 Prism web pages.
For inquiries about i3 Genesis and i3 Accelerator, please reach out to Louise Lammers, PhD, Director, Business Development, Emerging Assets at email@example.com or William Chiang, PhD, Business Development Consultant, at firstname.lastname@example.org. For inquiries about i3 Prism, please reach out to Cynthia Cleto, MS, Senior Director of Outreach, Entrepreneurship and Special Programs at email@example.com or Steffanie Haripersaud, MHA, Program Manager, at firstname.lastname@example.org.